4//SEC Filing
PATUSKY CHRISTOPHER 4
Accession 0001562180-25-000328
CIK 0001082554other
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 4:30 PM ET
Size
20.1 KB
Accession
0001562180-25-000328
Insider Transaction Report
Form 4
PATUSKY CHRISTOPHER
Director
Transactions
- Exercise/Conversion
Common Stock
2025-01-10$175.43/sh+5,000$877,150→ 5,900 total - Sale
Common Stock
2025-01-10$362.03/sh−1,930$698,724→ 2,101 total - Sale
Common Stock
2025-01-10$361.04/sh−969$349,850→ 4,031 total - Sale
Common Stock
2025-01-10$363.86/sh−109$39,661→ 900 total - Sale
Common Stock
2025-01-10$358.65/sh−300$107,596→ 5,600 total - Sale
Common Stock
2025-01-10$359.82/sh−600$215,893→ 5,000 total - Sale
Common Stock
2025-01-10$362.95/sh−1,092$396,347→ 1,009 total - Exercise/Conversion
Stock Option
2025-01-10−5,000→ 5,000 totalExercise: $175.43From: 2016-06-26Exp: 2025-06-26→ Common Stock (5,000 underlying)
Holdings
- 1,100(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 27, 2024.
- [F2]This transaction was executed in multiple trades at prices ranging from $358.11 to $358.895. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. the price reported above reflects the weighted average sale price.
- [F3]This transaction was executed in multiple trades at prices ranging from $359.12 to $360.095. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. the price reported above reflects the weighted average sale price.
- [F4]This transaction was executed in multiple trades at prices ranging from $360.395 to $361.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. the price reported above reflects the weighted average sale price.
- [F5]This transaction was executed in multiple trades at prices ranging from $361.485 to $362.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. the price reported above reflects the weighted average sale price.
- [F6]This transaction was executed in multiple trades at prices ranging from $362.49 to $363.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. the price reported above reflects the weighted average sale price.
- [F7]This transaction was executed in multiple trades at prices ranging from $363.80 to $364.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. the price reported above reflects the weighted average sale price.
Documents
Issuer
UNITED THERAPEUTICS Corp
CIK 0001082554
Entity typeother
Related Parties
1- filerCIK 0001231427
Filing Metadata
- Form type
- 4
- Filed
- Jan 12, 7:00 PM ET
- Accepted
- Jan 13, 4:30 PM ET
- Size
- 20.1 KB